Single Low-Dose Nanovaccine for Long-Term Protection against Anthrax Toxins,Nano Letters

当前位置： X-MOL 学术 › Nano Lett. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Single Low-Dose Nanovaccine for Long-Term Protection against Anthrax Toxins
Nano Letters ( IF 9.6 ) Pub Date : 2022-11-30 , DOI: 10.1021/acs.nanolett.2c03881
Maya Holay ₁ , Nishta Krishnan ₁ , Jiarong Zhou ₁ , Yaou Duan ₁ , Zhongyuan Guo ₁ , Weiwei Gao ₁ , Ronnie H Fang ₁ , Liangfang Zhang ₁

Affiliation

Anthrax infections caused by Bacillus anthracis are an ongoing bioterrorism and livestock threat worldwide. Current approaches for management, including extended passive antibody transfusion, antibiotics, and prophylactic vaccination, are often cumbersome and associated with low patient compliance. Here, we report on the development of an adjuvanted nanotoxoid vaccine based on macrophage membrane-coated nanoparticles bound with anthrax toxins. This design leverages the natural binding interaction of protective antigen, a key anthrax toxin, with macrophages. In a murine model, a single low-dose vaccination with the nanotoxoids generates long-lasting immunity that protects against subsequent challenge with anthrax toxins. Overall, this work provides a new approach to address the ongoing threat of anthrax outbreaks and bioterrorism by taking advantage of an emerging biomimetic nanotechnology.

中文翻译：

单一低剂量纳米疫苗可长期预防炭疽毒素

由炭疽杆菌引起的炭疽感染是全球范围内持续存在的生物恐怖主义和牲畜威胁。目前的管理方法，包括延长被动抗体输注、抗生素和预防性疫苗接种，通常很麻烦，并且患者依从性较低。在这里，我们报告了基于与炭疽毒素结合的巨噬细胞膜包被纳米颗粒的佐剂纳米类毒素疫苗的开发。该设计利用了保护性抗原（一种关键的炭疽毒素）与巨噬细胞的自然结合相互作用。在小鼠模型中，单次低剂量纳米类毒素疫苗接种可产生持久的免疫力，防止随后受到炭疽毒素的攻击。总体而言，这项工作提供了一种新方法，通过利用新兴的仿生纳米技术来应对炭疽爆发和生物恐怖主义的持续威胁。

更新日期：2022-11-30

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11